Orthocell Ltd (ASX: OCC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Orthocell Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$149.82 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
272.39 million
Earnings per share
-0.053
Dividend per share
N/A
Year To Date Return
-49.31%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Orthocell Ltd (ASX: OCC)
Latest News
Share Gainers
Why Elders, Netwealth, Orthocell, and Syrah shares are charging higher
Share Gainers
Why Bravura, Dateline, Orthocell, and Race Oncology shares are storming higher
Healthcare Shares
Up 273% in a year, guess which ASX All Ords stock is leaping higher today on a new record
Share Gainers
Why Bellevue Gold, DroneShield, Orthocell, and Restaurant Brands NZ shares are rising today
Small Cap Shares
Guess which ASX share is jumping 8% on big North American news
Healthcare Shares
Guess which ASX All Ords stock is jumping 10% on exciting news
Share Gainers
Why 4DMedical, DroneShield, Orthocell, and Resolute Mining shares are racing higher
Best Shares
8 ASX All Ords shares that tripled in value in FY25
Share Gainers
Why Evolution Mining, Orthocell, Platinum, and Turaco shares are charging higher
Healthcare Shares
Guess which ASX All Ords stock is jumping on big US news
Healthcare Shares
Up 250% in a year, how much higher can this ASX healthcare share climb?
Share Gainers
Why DroneShield, Medibank, Orthocell, and Santana Minerals shares are pushing higher
OCC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Orthocell Ltd
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. Its products include CelGro which is a naturally derived collagen medical device for soft tissue repair, and Antilogous Tenocyte Implantation (Ortho-ATI) for chronic, treatment resistant tendon injuries. The company was founded by Paul Anderson and Min Hao Zheng on March 21, 2006 and is headquartered in Murdoch, Australia.
OCC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 30 Oct 2026 | $0.55 | $0.02 | 3.74% | 92,728 | $0.54 | $0.56 | $0.53 |
| 29 Oct 2026 | $0.54 | $-0.01 | -1.85% | 165,019 | $0.54 | $0.56 | $0.54 |
| 28 Oct 2026 | $0.54 | $0.01 | 1.87% | 362,148 | $0.55 | $0.55 | $0.53 |
| 27 Oct 2026 | $0.54 | $0.04 | 8.08% | 1,033,417 | $0.49 | $0.57 | $0.49 |
| 26 Oct 2026 | $0.50 | $-0.02 | -3.88% | 720,360 | $0.52 | $0.52 | $0.49 |
| 23 Oct 2026 | $0.52 | $-0.01 | -1.90% | 1,115,300 | $0.53 | $0.55 | $0.50 |
| 22 Oct 2026 | $0.53 | $-0.07 | -11.67% | 2,498,872 | $0.60 | $0.60 | $0.51 |
| 21 Oct 2026 | $0.60 | $-0.05 | -7.69% | 1,257,707 | $0.65 | $0.65 | $0.60 |
| 20 Oct 2026 | $0.65 | $0.00 | 0.00% | 283,456 | $0.66 | $0.66 | $0.63 |
| 19 Oct 2026 | $0.65 | $-0.02 | -2.99% | 321,657 | $0.67 | $0.67 | $0.64 |
| 16 Oct 2026 | $0.67 | $0.03 | 4.65% | 445,442 | $0.66 | $0.68 | $0.65 |
| 15 Oct 2026 | $0.65 | $-0.02 | -3.03% | 425,356 | $0.66 | $0.66 | $0.63 |
| 14 Oct 2026 | $0.66 | $-0.02 | -2.94% | 437,931 | $0.68 | $0.69 | $0.66 |
| 13 Oct 2026 | $0.68 | $0.01 | 1.49% | 703,725 | $0.74 | $0.74 | $0.67 |
| 12 Oct 2026 | $0.67 | $-0.02 | -2.90% | 515,444 | $0.69 | $0.71 | $0.67 |
| 09 Oct 2026 | $0.69 | $-0.01 | -1.44% | 134,625 | $0.70 | $0.71 | $0.69 |
| 08 Oct 2026 | $0.70 | $-0.02 | -2.82% | 282,338 | $0.71 | $0.71 | $0.69 |
| 07 Oct 2026 | $0.71 | $-0.01 | -1.39% | 501,267 | $0.74 | $0.74 | $0.70 |
| 06 Oct 2026 | $0.72 | $-0.04 | -5.26% | 459,607 | $0.75 | $0.75 | $0.71 |
| 05 Oct 2026 | $0.76 | $0.00 | 0.00% | 192,924 | $0.74 | $0.76 | $0.74 |
| 02 Oct 2026 | $0.76 | $-0.01 | -1.31% | 313,401 | $0.76 | $0.77 | $0.74 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 20 Jul 2026 | John Wielen | Issued | 15,430 | $11,666 |
As advised by the company. Adjustment to Director Fee Shares issued on 17/07/2026.
|
| 17 Jul 2026 | Michael McNulty | Issued | 11,573 | $8,750 |
Director remuneration.
|
| 17 Jul 2026 | Fiona Wood | Issued | 11,573 | $8,750 |
Director remuneration.
|
| 17 Jul 2026 | Ravi Thadhani | Issued | 16,603 | $12,554 |
Director remuneration.
|
| 17 Jul 2026 | John Wielen | Issued | 23,145 | $17,500 |
Director remuneration.
|
| 01 May 2026 | John Wielen | Buy | 25,000 | $23,310 |
On-market trade.
|
| 30 Apr 2026 | Michael McNulty | Buy | 23,615 | $21,050 |
On-market trade. https://www.aspecthuntley.com.au/asxdata/20260717/pdf/03112041.pdf
|
| 25 Feb 2026 | Michael McNulty | Buy | 26,041 | $25,031 |
On-market trade. https://www.aspecthuntley.com.au/asxdata/20260717/pdf/03112041.pdf
|
| 25 Feb 2026 | John Wielen | Buy | 32,500 | $31,337 |
On-market trade.
|
| 22 Dec 2025 | Paul Anderson | Exercise | 126,580 | $132,276 |
Conversion of securities. 2073586 rights
|
| 22 Dec 2025 | Paul Anderson | Buy | 126,580 | $132,276 |
Conversion of securities.
|
| 28 Nov 2025 | Paul Anderson | Issued | 52,078 | $55,723 |
Issue of securities. 2,200,166 rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Professor Fiona Melanie Wood | Non-Executive Director | Nov 2023 |
Ms Wood is a plastic and reconstructive surgeon with more than 30 years'experience. Professor Wood was appointed a Member of the Order of Australia in 2003 and was named Australian of the Year in 2005 for her contribution to medicine and burns treatment.
|
| Mr Paul Frederick Anderson | Chief Executive OfficerManaging Director | Mar 2006 |
Mr Anderson has more than 25 years'experience in medical devices and cellular therapeutics, with expertise in translating research into clinical and commercial products. His experience spans strategic planning, new product development, product launches, international regulatory pathways, reimbursement, marketing, sales and key opinion leader engagement. Paul previously held the Managing Director's position with Verigen Australia Pty Ltd, a human cell therapies company acquired by Nasdaq-listed Vericel Corporation, a multi-billion-dollar biotechnology company focused on cell therapies and specialty biologics. He has more than 20 years'experience in executive leadership and board roles and has experience in bringing regenerative medicine technologies from research through to clinical adoption and market entry.
|
| Dr Ravi Thadhani | Lead Independent DirectorNon-Executive Director | Mar 2023 |
Dr Thadhani is a recognised healthcare executive, physician and researcher with more than 30 years'experience in clinical medicine, research, medical administration and commercialisation. He is Executive Vice President, Chief Physician Executive and Dean of the Medical Faculty at Cedars-Sinai, where he cheks the organisation's academic and clinical enterprises. Dr Thadhani has authored more than 300 scientific publications and has experience in patient care, novel research programs, US regulatory pathways and the commercialisation of medical devices and therapeutics. He has served on multiple US FDA advisory committees and has acted as an adviser to a number of global pharmaceutical and healthcare organisations.
|
| Mr John Van Der Wielen | Non-Executive ChairmanNon-Executive Director | Jun 2023 |
Mr Wielen is an executive leader with more than 30 years'experience across wealth management, private banking, investments and insurance. He has held senior roles with global financial services groups and has experience in capital markets, institutional investor engagement, acquisitions, integration and business transformation. He is also a senior adviser to Appian Capital Advisory LLP & Bridgewest Group.
|
| Mr Michael McNulty | Non-Executive Director | Sep 2025 |
Mr McNulty has more than 35 years'professional experience, including 22 years as a Deloitte partner and senior leadership roles across Deloitte Australia and Asia Pacific. He is also Vice-President and Board member of Cancer Council WA. He is the chairperson of the risk committee.
|
| Mr Peter Webse | Company Secretary | Mar 2023 |
-
|
| Jim Piper | CFO |
-
|
|
| Peter Webse | Company Secretary |
-
|
|
| Alex McHenry | COO |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Ming Hao Zheng & Ying Fan <The Zheng A/C> | 7,098,346 | 2.61% |
| Hsbc Custody Nominees (Australia) Limited | 6,572,292 | 2.41% |
| Paul Frederick Anderson & Nicole Jane Telford | 6,233,335 | 2.29% |
| Qixiao Zhou | 6,223,925 | 2.29% |
| Citicorp Nominees Pty Limited | 5,223,772 | 1.92% |
| Wyllie Group Pty Ltd-i | 5,076,924 | 1.86% |
| Wyllie Group Pty Ltd-ii | 4,501,072 | 1.65% |
| Jiaxun Xu | 4,478,480 | 1.64% |
| Patrick John McHale | 4,380,000 | 1.61% |
| J P Morgan Nominees Australia Pty Limited | 4,086,065 | 1.50% |
| Rubino Group Pty Ltd <Rubino Group A/C> | 2,506,411 | 0.92% |
| The University of Western Australia | 2,360,973 | 0.87% |
| John Clifford Philpott & Rebecca Anne Philpott <Philpott Super Fund A/C> | 2,124,677 | 0.78% |
| Sandini Pty Ltd <Karratha Rigging Unit A/C> | 1,977,219 | 0.73% |
| BNP Paribas Nominees Pty Ltd | 1,759,342 | 0.65% |
| John Clifford Philpott | 1,620,520 | 0.60% |
| CG Nominees (Australia) Pty Ltd | 1,500,000 | 0.55% |
| David Gordon Trainer | 1,375,000 | 0.50% |
| Kim Christian Beazley | 1,350,900 | 0.50% |
| Shortclan Investments Pty Ltd <Short Family Super Fund A/C> | 1,300,000 | 0.48% |
